453 results on '"Compton, Chris"'
Search Results
2. Correction: Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
3. A scoping review on the epidemiology and public significance of Brucella abortus in Chinese dairy cattle and humans
4. Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study
5. A novel Bayesian Latent Class Model (BLCM) evaluates multiple continuous and binary tests: A case study for Brucella abortus in dairy cattle
6. Get the timing right for good results
7. High risk just before calving
8. Sustainability of seasonal calving questioned
9. Do the wheels fall off if you stop inducing cows?
10. A Response to: Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis”
11. Drainage investment recouped within 3 seasons
12. Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis
13. Interhemispheric inhibition is different during arm cycling than a position- and intensity-matched tonic contraction
14. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis
15. Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD
16. Structural Predictors of Lung Function Decline in Young Smokers with Normal Spirometry
17. Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study
18. Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany
19. Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial
20. Something for everyone: From conference stream overviews to analyses of specific sessions and talks, this year's conference round-up covers all the bases.
21. Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany
22. Correction to: Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis
23. Evaluation of Adherence and Persistence to Triple Therapy in Patients with COPD: A German Claims Data Study.
24. Understanding the Gaps in the Reporting of COPD Exacerbations by Patients: A Review
25. Treatment pathways, economic burden and clinical outcomes in new users of inhaled corticosteroid/long-acting B2-agonist dual therapy with chronic obstructive pulmonary disease in a primary care setting in England: a retrospective cohort study
26. Going North in 1863
27. Efficacy of umeclidinium/vilanterol according to the degree of reversibility of airflow limitation at screening: a post hoc analysis of the EMAX trial
28. Single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) triple therapy versus tiotropium monotherapy in patients with COPD
29. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial
30. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials
31. Association between blood eosinophils and acute exacerbation of COPD risk in patients with COPD in primary care
32. Risk Factors Associated with a First Exacerbation Among Patients with COPD Classified as GOLD A and B in Routine Clinical Practice in the UK
33. How can the findings of the EMAX trial on long-acting bronchodilation in chronic obstructive pulmonary disease be applied in the primary care setting?
34. Persistence to inhaled long-acting maintenance therapy in patients with COPD in UK routine clinical practice
35. Recognising exacerbations in Early COPD
36. Economic benefit of fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) by baseline blood eosinophil (EOS) count in COPD in the UK - The IMPACT trial
37. Cost-Effectiveness of Umeclidinium/Vilanterol Versus Indacaterol/Glycopyrronium in Symptomatic patients with COPD in the UK
38. Use of the CAPTURE case-finding tool to identify COPD patients who may need treatment
39. COPD Assessment Test (CAT) Score according to the presence/absence of accelerated lung function decline in young adult smokers with normal FEV1
40. Characteristics and treatment pathways of COPD patients initiating single-inhaler dual or triple therapy in England
41. Cost-Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Versus Glycopyrrolate/Formoterol Fumarate (GLY/FOR) in Symptomatic Patients with COPD in the UK: The AERISTO trial
42. Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England
43. Umeclidinium/Vilanterol Versus Tiotropium/Olodaterol in Maintenance-Naïve Patients with Moderate Symptomatic Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis
44. Use of CAPTURE to Identify Individuals Who May or May Not Require Treatment for Chronic Obstructive Pulmonary Disease
45. Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK
46. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials
47. Risk factors for exacerbations and pneumonia in patients with chronic obstructive pulmonary disease: a pooled analysis
48. Comparison of Rescue Medication Prescriptions in Patients with Chronic Obstructive Pulmonary Disease Receiving Umeclidinium/Vilanterol versus Tiotropium Bromide/Olodaterol in Routine Clinical Practice in England
49. Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis
50. Efficacy of Umeclidinium/Vilanterol in Elderly Patients with COPD: A Pooled Analysis of Randomized Controlled Trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.